Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Lisa LaMotta

Advertisement

Articles by Lisa LaMotta

5-FU Dose Optimization: Another Step Towards Personalizing Cancer Care

ByLisa LaMotta
May 5th 2010

According to the Centers for Disease Control and Prevention, colorectal cancer is the second leading cancer killer in the United States, affecting both men and women.

Advertisement

Latest Updated Articles

  • 5-FU Dose Optimization: Another Step Towards Personalizing Cancer Care
    5-FU Dose Optimization: Another Step Towards Personalizing Cancer Care

    May 5th 2010



Advertisement
Advertisement

Trending on OncLive

1

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

2

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

3

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

4

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

5

FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us